Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, outperforming placebo. The FDA approval of oral semaglutide marks the first GLP-1 pill for chronic weight management, ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/trial-workflows ...
Adaptive workflow systems represent a significant departure from rigid, process-centric approaches. Instead of imposing a linear, step-by-step structure, teams will be able to dynamically assign and ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback